Skip to content
MarketScale
‹ Back to IndustriesHealthcare

USP CLASS VI CERTIFICATION

The complexities of medical device bio-compatibility can be difficult to navigate. In this post, we will explain how plastics are classified and tested to ensure patient safety. The U.S. Pharmacopeial Convention (USP) is a nonprofit organization responsible for creating standards for a variety of healthcare elements, including devices and equipment. The USP promotes bio-compatibility for…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

The complexities of medical device bio-compatibility can be difficult to navigate. In this post, we will explain how plastics are classified and tested to ensure patient safety.

The U.S. Pharmacopeial Convention (USP) is a nonprofit organization responsible for creating standards for a variety of healthcare elements, including devices and equipment. The USP promotes bio-compatibility for plastics and polymers that come in contact with patient tissue. For these materials, there are six classes, with VI being the most stringent. While the first five classifications are valuable for certain materials, Class VI is the most compatible for medical applications.

USP Class VI – Three Evaluations to Ensure Safety

For the USP Class VI, there are three tests that materials must meet to be deemed safe. There are four standards that these evaluations test: purity, strength, quality and consistency. Here are the three tests explained:

  • Acute Systemic Toxicity measures the toxicity and irritation when a sample of the material is administered orally, placed on the skin or inhaled. It is extracted in up to four solutions: saline, vegetable oil, alcohol saline and polyethylene glycol. The test model is then observed for three days to determine any ill effects.
  • Intracutaneous determines the material’s toxicity and localized irritation when it touches live skin. It is extracted using the same four solutions. Test and control sites are compared to see if there is any significant reaction.
  • Implantation assesses toxicity, infection and irritation of intramuscular These implantations are observed for five to seven days to determine if there is any negative response.

These tests focus on toxicity while evaluating temperature over specific time periods. If a material does meet rigorous USP Class VI standards, then it is likely to be accepted by the FDA and USDA. Class VI testing encompasses any kind of possible applications that include the standard polar and nonpolar extracts required for ISO 10993-12 for completed devices. It’s considered the gold standard for medical-grade raw materials.

The USP Class testing was initially intended for polymers but can also be used to test other materials that encounter patients. The Class labels are meant to represent real-world usage.

EVA from Presco Meets Class VI

EVA (ethylene-vinyl acetate), is a copolymer consisting of ethylene and vinyl acetate. This medical grade film is a soft, clear material that can be RF-welded to create medical solution containers and tubing sets.

With rising concerns regarding the use of PVC in medical applications, EVA has been found to be a suitable alternative for medical use. In fact, for medical bags, EVA is the preferred choice—it has proven track record spanning three decades of wide use in medical device applications, particularly in IV therapy.

Why Choose EVA?

  • 30% lighter than PVC for a better yield and lower shipping costs
  • EVA has better tear and burst strength
  • Exceptional sealing properties
  • Strong impact resistance and cold crack properties
  • Meets all regulatory requirements of the market
  • Bio-compatible as certified with USP Class VI testing
  • No plasticizers or chlorine
  • Printable for fill lines

Pres-Flex EVA is Presco’s first PVC-free manufacturing capability for engineered film. To learn more about USP Class VI certified EVA film from Presco, contact us today. Our team of experienced professionals can guide you through your organization’s unique needs to determine whether this highly-favored PVC alternative is appropriate for your manufacturing processes.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Healthcare expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

OpenEvidence expands clinical AI across NewYork-Presbyterian, Columbia, and Weill Cornell as Linux Foundation targets open-source health stack

OpenEvidence expands clinical AI across NewYork-Presbyterian, Columbia, and Weill Cornell as Linux Foundation targets open-source health stack

OpenEvidence is expanding its clinical AI technologies across major New York healthcare institutions including NewYork-Presbyterian, Columbia, and Weill Cornell. Concurrently, the Linux Foundation is establishing efforts to create an open-source health technology stack. Delaware is expanding its Health Information Exchange (HIE) access.

  • 01OpenEvidence expands clinical AI deployment in prominent New York-based healthcare facilities.
  • 02The Linux Foundation is developing an open-source stack for healthcare technology.
  • 03Delaware is enhancing access to its Health Information Exchange (HIE).

Jul 22, 2026

AI agents for patient care draw $335 million in a single month as health tech investment accelerates

AI agents for patient care draw $335 million in a single month as health tech investment accelerates

In June 2026, four health tech companies secured significant funding, totaling $335 million. AI agent platforms for scheduling, chronic care, and home health dominated these investment rounds. This trend reflects a growing interest in leveraging AI for improving patient care in the healthcare sector.

  • 01In June 2026, four health tech companies collectively attracted $335 million in funding.
  • 02AI platforms for chronic care management, scheduling, and home health are leading current health tech investments.
  • 03Investors are increasingly interested in AI technologies that enhance patient care in healthcare.

Jul 20, 2026

Healthcare's digital skills gap: why existing competency tools aren't built for the full workforce

Healthcare's digital skills gap: why existing competency tools aren't built for the full workforce

Reviews have revealed that current competency tools in healthcare are inadequate for measuring and developing digital skills among both clinical and public health teams. These tools fail to address the comprehensive needs required for the evolving digital landscape in healthcare. Addressing this skills gap is crucial for the effective digital transformation of health systems.

  • 01Current digital competency tools in healthcare do not adequately cover the full workforce.
  • 02Improved measurement and development of digital skills are needed across clinical and public health teams.
  • 03Addressing the digital skills gap is essential for successful healthcare transformation.

Jul 19, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512